Prostate Cancer Survival Rates Jump with Drug Combination, Major Study Finds
LOS ANGELES, CA – A new eight-year study from teh Cedai-Sinar Cancer Center in Los Angeles reveals a significant improvement in survival rates for men with cancer-music/” title=”Rage Against The Machine Bassist Fights Prostate … | Music”>prostate cancer when treated with a combination of the drugs enzalutamide adn leuprolide. The findings, published and reported by New Atlas, offer a potential breakthrough in combating the disease, particularly in cases where cancer returns after initial treatment.
Approximately 40% of men experience prostate cancer recurrence following first-line therapies, often with a more aggressive form of the disease.”After a first treatment, some patients see their prostate cancer return aggressively and risk that the disease spreads quickly,” explained a co-author of the study.
The research, involving over 1,000 participants from 17 countries, divided patients into three groups: one receiving enzalutamide, another receiving leuprolide, and a third receiving both drugs concurrently. While the first two groups showed no significant improvement, the combination therapy demonstrated a 40.3% increase in survival rates after an average of eight years of follow-up.
Importantly, both enzalutamide and leuprolide are already approved for use in prostate cancer treatment by the Food and Drug administration in the United States. Researchers anticipate these results will expedite the approval process for the combined therapy, offering a potentially life-saving option for a wider range of patients.
